NCT01789814View on ClinicalTrials.gov

Effect of Prasugrel Versus Clopidogrel on Platelet Function After Bivalirudin Cessation

PHASE4CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions
Coronary Artery Disease
Interventions
DRUG

Prasugrel

Patients will be randomized to prasugrel or clopidogrel to assess the effect of these drugs on inhibition of platelet aggregation following the cessation of bivalirudin therapy.

DRUG

Clopidogrel

Clopidogrel 600 mg as a loading dose immediately prior to the start of procedure and 75 mg daily thereafter

Trial Locations (1)

02111

Tufts Medical Center, Boston

All Listed Sponsors
lead

Tufts Medical Center

OTHER

NCT01789814 - Effect of Prasugrel Versus Clopidogrel on Platelet Function After Bivalirudin Cessation | Biotech Hunter | Biotech Hunter